Trial watch: chemotherapy-induced immunogenic cell death in oncology
Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …
death that activates, rather than suppresses, innate and adaptive immune responses. Such …
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a …
Background In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab
showed superior efficacy over sunitinib in patients with previously untreated intermediate …
showed superior efficacy over sunitinib in patients with previously untreated intermediate …
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma …
Background The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of …
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of …
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting
B Beuselinck, S Job, E Becht, A Karadimou… - Clinical cancer …, 2015 - AACR
Purpose: Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who
might benefit from treatment with targeted tyrosine kinase inhibitors (TKI) is a challenge. Our …
might benefit from treatment with targeted tyrosine kinase inhibitors (TKI) is a challenge. Our …
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …
development over recent decades. However, this field is currently in a state of flux toward …
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
MC Southey, DE Goldgar, R Winqvist… - Journal of medical …, 2016 - jmg.bmj.com
Background The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate
precisely associated cancer risks. Population-based family studies have provided evidence …
precisely associated cancer risks. Population-based family studies have provided evidence …
Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival
Importance There exists considerable biological and clinical variability between histologic
variants of metastatic renal cell carcinoma (mRCC). Data reporting on patterns of metastasis …
variants of metastatic renal cell carcinoma (mRCC). Data reporting on patterns of metastasis …
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz… - The lancet …, 2019 - thelancet.com
Background Cabozantinib is approved for patients with metastatic renal cell carcinoma on
the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with …
the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with …
[HTML][HTML] Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib
B Beuselinck, S Oudard, O Rixe, P Wolter, A Blesius… - Annals of oncology, 2011 - Elsevier
Background The aim of our study was to determine whether the presence of bone
metastases affects outcomes in patients with metastatic clear-cell renal cell carcinoma (m …
metastases affects outcomes in patients with metastatic clear-cell renal cell carcinoma (m …
Sunitinib for the treatment of metastatic renal cell carcinoma
S Oudard, B Beuselinck, J Decoene, P Albers - Cancer treatment reviews, 2011 - Elsevier
Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor approved
multinationally for the first-and second-line treatment of metastatic renal cell carcinoma …
multinationally for the first-and second-line treatment of metastatic renal cell carcinoma …